SY-5609

Decreasing Expression of Cancer-Driving Genes with CDK7
AnneOvarian Cancer Survivor

Decreasing Expression of Cancer-Driving Genes with CDK7

SY-5609 is a highly selective and potent oral inhibitor of the cyclin-dependent kinase 7 (CDK7) that is expected to enter a Phase 1 clinical trial in patients with select solid tumors, including breast, lung and ovarian cancers, as well as solid tumors of any histology with a specific molecular signature.

SY-5609 represents a new approach to treating cancer that we believe has potential in a range of difficult-to-treat cancers. It has induced deep and sustained tumor growth inhibition, including complete regressions, as a single agent in preclinical models of breast, ovarian and lung cancers. SY-5609 has also shown substantial anti-tumor activity in combination with fulvestrant in hormone receptor (HR)-positive breast cancer models that are resistant to CDK4/6 inhibitors. SY-5609 has also been shown preclinically to preferentially kill cancer cells over non-cancerous cells.

A Promising Approach for Difficult-to-Treat Cancers

Cancer cells adapt to hijack or thwart the body’s normal processes to grow out of control, forming tumors and crowding out healthy cells. SY-5609 has the potential to disrupt two important processes that cancer cells use to survive and thrive: increased expression of cancer-promoting genes, and uncontrolled cell cycle progression.

Potent and Highly Selective CDK7 Inhibitor

Program Indication Discovery Preclinical Early Clinical Mid-Stage Clinical Pivotal Commercial Rights
SY-5609 (Oral CDK7 inhibitor)
SY-5609 (Oral CDK7 inhibitor)
Cancer
Discovery Phase complete
Preclinical Phase in progress
Early Clinical Phase not started
Mid-Stage Clinical Phase not started
Pivotal Phase not started
Syros (Global)
Syros (Global)

Interested in Participating in a Clinical Trial?

If you’re interested in participating in a clinical trial, check to see if a trial is open near your area and if you meet the requirements to participate.

Learn More